Perspective Therapeutics (CATX) Depreciation & Amortization (CF) (2010 - 2026)

Perspective Therapeutics (CATX) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 53.83% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $3.6 million (up 35.91% YoY), and the FY2025 full-year result was $3.3 million, up 40.98% from the prior year.
• Depreciation & Amortization (CF) advanced to $1.1 million in Q1 2026, from $1.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.1 million in Q1 2026 to a low of $74000.0 in Q1 2022.
• A 5-year average of $485117.6 and a median of $356000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) soared 276.92% in 2022 and gained 15.84% in 2025, its largest moves.
• Tracing CATX's Depreciation & Amortization (CF) over 5 years: stood at $138000.0 in 2022, then soared by 118.84% to $302000.0 in 2023, then jumped by 134.77% to $709000.0 in 2024, then jumped by 42.6% to $1.0 million in 2025, then grew by 11.37% to $1.1 million in 2026.
• Business Quant data shows CATX's Depreciation & Amortization (CF) at $1.1 million in Q1 2026, $1.0 million in Q4 2025, and $775000.0 in Q3 2025.